CANNABINOID FORMULATIONS

• US 20160030387A1
• Filed: 08/03/2015
• Published: 02/04/2016
• Est. Priority Date: 07/11/2011
• Status: Active Grant

• Current Assignee: Teewinot Technologies Limited (Teewinot Life Sciences Corp.)
• Original Assignee: Full Spectrum Laboratories Limited
• Inventors: WINNICKI, Robert
• Granted Patent: US 10,052,303 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A23L 33/105 Plant extracts, their artificial duplicates or their derivatives
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A61K 31/05 Phenols cannabinoids A61K31/658
• CPC Class Codes: A61K 31/352 condensed with carbocyclic rings, e.g. methantheline cannabinoids A61K31/658
• CPC Class Codes: A61K 36/185 Magnoliopsida (dicotyledons)
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/24 containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• CPC Class Codes: A61K 47/36 Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• CPC Class Codes: A61K 9/107 Emulsions ; Emulsion preconcentrates; Micelles composition of emulsions A61K47/00
• CPC Class Codes: A61K 9/1075 Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers A61K9/0026 takes precedence
• CPC Class Codes: A61K 9/127 Liposomes

Abstract

The present invention provides stable, fast-acting liposomal and micelle formulations of cannabinoids that are suitable for pharmaceutical and nutraceutical applications.

Claims

1-27. -27. (canceled)

28. A formulation comprising a unilamellar micelle or liposome suspension of one or more cannabinoids or cannabinoid analogues, wherein the suspension comprises unilamellar micelles or liposomes that are thermostable at temperatures greater than 50°

C.

29. The formulation of claim 28, wherein the one or more cannabinoids or cannabinoid analogues are one or more of a natural compound, a synthetic compound, a semi-synthetic compound, or mixtures thereof.

30. The formulation of claim 29, wherein the one or more cannabinoids or cannabinoid analogues are one or more of cannabinol, cannabidiol, Δ

9-tetrahydrocannabinol, Δ

8-tetrahydrocannabinol, 11-hydroxy-tetrahydrocannabinol, 11-hydroxy-Δ

9-tetrahydrocannabinol, levonantradol, Δ

11-tetrahydrocannabinol, tetrahydrocannabivarin, dronabinol, amandamide, nabilone, a combination thereof, a natural or synthetic analogue thereof, or a natural or synthetic molecule with a basic cannabinoid structure.

31. The formulation of claim 28, wherein the formulation is a liquid dosage form, a solid dosage form, a composition for parenteral injection, a dietary composition or a dosage form for topical administration.

32. The formulation of claim 31, wherein the formulation is a liquid dosage form comprising an emulsion, a solution, a suspension, a syrup or an elixir.

33. The formulation of claim 31, wherein the formulation is a solid dosage form comprising an extract, a capsule, a tablet, a pill, a dragee, a powder or a granule, and wherein the formulation further comprises one or more of a pharmaceutically acceptable excipient, a carrier, a filler, a binder, a disintegrating agent, a humectant, an absorption accelerator, a wetting agent, an absorber, a lubricant and a buffering agent.

34. The formulation of claim 33, wherein the solid dosage form comprises a coating, and wherein the coating is an enteric coating, an extended-release coating, a sustained-release coating, a delayed release coating or an immediate release coating.

35. The formulation of claim 31, wherein the formulation is a dosage form for topical administration comprising an ointment, a cream, an emulsion, a lotion, a gel, a sunscreen or an agent that favors penetration into the skin.

36. The formulation of claim 31, wherein the formulation is a composition for parenteral injection comprising a pharmaceutically acceptable sterile aqueous or non-aqueous solution, a dispersion, a suspension, an emulsion, a powder or a depot injectable formulation.

37. The formulation of claim 31, wherein the dietary composition is nutraceutical, a soup, a baking good, a dairy product, a meat product, a fish product, a vegetable product or a fruit product.

38. The formulation of claim 28, further comprising a stabilizer selected from the group consisting of guar gum, xanthan gum cellulose hyaluronic acid, polyvinyl pyrrolidone (PVP), alginate, chondritin sulfate, poly gamma glutamic acid, gelatin, chitisin, corn starch and flour, in an amount from about 0.25% to about 2% (w/v).

39. The formulation of claim 28, wherein the formulation comprises a unilamellar micelle suspension of one or more cannabinoids or cannabinoid analogues, and wherein the average micelle diameter size is in a range between 50 and 1000 nm.

40. The formulation of claim 39, wherein the concentration of cannabinoids or cannabinoid analogues in the suspension is from about 1 g/l to about 2 g/liter.

41. The formulation of claim 28, wherein the formulation comprises a liposomal suspension of one or more cannabinoids or cannabinoid analogues, and wherein the liposomes have an average diameter size from about 100 nm to about 400 nm.

42. The formulation of claim 41, wherein the concentration of one or more cannabinoids or cannabinoid analogues in the suspension is from about 10 mg/ml to about 300 mg/ml.

43. A method of producing a formulation comprising a unilamellar micelle or liposome suspension of one or more cannabinoids or cannabinoid analogues according to claim 28, wherein the method comprises the steps of:

(a) dissolving one or more cannabinoids or cannabinoid analogues in a solvent;

(b) adding a phospholipid to the cannabinoid solution;

(c) injecting the cannabinoid solution from step (b) into distilled water to obtain a cannabinoid suspension;

(d) removing the solvent;

(e) adding an encapsulant to the formulation of step (d) to obtain an encapsulated cannabinoid formulation;

(f) cold-pressing and air-drying or shell-freezing the encapsulated cannabinoid formulation to obtain a dry cannabinoid powder; and

(h) milling and re-suspending the dry cannabinoid powder in an aqueous solution;

and wherein the amount of cannabinoids or cannabinoid analogues in the aqueous cannabinoid solution is greater than 40%.

44. The method of claim 43, wherein the one or more cannabinoids or cannabinoid analogues are one or more of a natural compound, a synthetic compound, a semi-synthetic compound, or mixtures thereof.

45. The method of claim 44, wherein the one or more cannabinoids or cannabinoid analogues are cannabinol, cannabidiol, Δ

9-tetrahydrocannabinol, Δ

8-tetrahydrocannabinol, 11-hydroxy-tetrahydrocannabinol, 11-hydroxy-Δ

9-tetrahydrocannabinol, levonantradol, Δ

11-tetrahydrocannabinol, tetrahydrocannabivarin, dronabinol, amandamide, nabilone, a combination thereof, a natural or synthetic analogue thereof, or a natural or synthetic molecule with a basic cannabinoid structure.

46. The method of claim 43, wherein the encapsulant is calcium alginate, L-leucine or a sugar.

47. A method of alleviating pain or reducing undesirable side effects associated with radiation therapy or chemotherapy in a subject having a compromised immune system, a cancer, a pulmonary disease or a condition that causes violent tremors comprising administering to the subject the formulation of claim 28.